Dose response with onabotulinumtoxinA for post-stroke spasticity: A pooled data analysis

Movement Disorders

Volumn 26, Issue 2, 2011, Pages 209-215

  Yablon, Stuart A ^a   Brin, Mitchell F ^b,c   Vandenburgh, Amanda M ^b   Zhou, Jihao ^b   Garabedian Ruffalo, Susan M ^d   Abu Shakra, Susan ^b   Beddingfield, Frederick C ^b,e  

^a BAYLOR HEALTH CARE SYSTEM   (United States)

^b ALLERGAN INC   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Ashworth Scale; Dose response; OnabotulinumtoxinA; Spasticity

Indexed keywords

BOTULINUM TOXIN A; PLACEBO;

ARM MUSCLE; ASHWORTH SCALE; DOSE RESPONSE; HUMAN; MULTICENTER STUDY (TOPIC); MUSCLE TONE; OUTCOME ASSESSMENT; POST STROKE SPASTICITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RATING SCALE; REVIEW; SPASTICITY; STROKE; STROKE PATIENT;

BOTULINUM TOXINS, TYPE A; CLINICAL TRIALS AS TOPIC; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; MUSCLE SPASTICITY; STROKE; TREATMENT OUTCOME;

EID: 79952667367     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.23426     Document Type: Review

References (24)

1. Gormley MEJr, O'Brien CF, Yablon SA. A clinical overview of treatment decisions in the management of spasticity. Muscle Nerve Suppl 1997; 6: S14-S20.
2. Thompson AJ, Jarrett L, Lockley L, et al. Clinical management of spasticity. J Neurol Neurosurg Psychiatry 2005; 76: 459-463.
3. Esquenazi A, Mayer NH. Instrumented assessment of muscle overactivity and spasticity with dynamic polyelectromyographic and motion analysis for treatment planning. Am J Phys Med Rehabil 2004; 83(10 Suppl): S19-S29.
4. National Stroke Association. Spasticity and paralysis treatment options. Available at: Accessed January 2010.
5. Satkunam LE. Rehabilitation medicine: 3. Management of adult spasticity. CMAJ 2003; 169: 1173-1179.
6. Simpson DM, Blitzer A, Brashear A, et al. Assessment: botulinum neurotoxin for the treatment of spasticity (an evidence-based review): report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 2008; 70: 1691-1698.
7. Yablon SA. Botulinum neurotoxin intramuscular chemodenervation. Role in the management of spastic hypertonia and related motor disorders. Phys Med Rehab Clin North Am 2001; 12: 833-874.
8. Dolly O. Synaptic transmission: Inhibition of neurotransmitter release by botulinum toxins. Headache 2003; 43(Suppl 1): S16-S24.
9. Brashear A, Gordon MF, Elovic E, et al. Intramuscular injection of botulinum toxin for the treatment of wrist and finger spasticity after a stroke. N Engl J Med 2002; 347: 395-400.
10. Elovic E, Brashear A, Kaelin D, et al. Repeated treatments with botulinum toxin type A produce sustained decreases in the limitations associated with focal upper-limb poststroke spasticity for caregivers and patients. Arch Phys Med Rehabil 2008; 89: 799-806.
11. Simpson DM, Alexander DN, O'Brien CF, et al. Botulinum toxin type A in the treatment of upper extremity spasticity: a randomized, double-blind, placebo-controlled trial. Neurology 1996; 46: 1306-1310.
12. Gordon MF, Brashear A, Elovic E, et al. Repeated dosing of botulinum toxin type A for upper limb spasticity following stroke. Neurology 2004; 63: 1971-1973.
13. Childers MK, Brashear A., Jozefczyk P, et al. Dose-dependent response to intramuscular botulinum toxin type A for upper-limb spasticity in patients after a stroke. Arch Phys Med Rehabil 2004; 85: 1063-1065.
14. Simpson DM, Gracies J-M, Yablon SA, et al. Botulinum neurotoxin versus tizanidine in upper limb spasticity: a placebo-controlled study. J Neurol Neurosurg Psychiatry 2009; 80: 380-385.
15. Turkel CC, Bowen B, Liu J, et al. Pooled analysis of the safety of botulinum toxin type A in the treatment of poststroke spasticity. Arch Phys Med Rehabil 2006; 87: 786-792.
16. Elia AE, Filippini G, Calandrella D, et al. Botulinum neurotoxins for post-stroke spasticity in adults: a systematic review. Mov Disord 2009; 24: 801-812.
17. Wissel J, Ward AB, Erztgaard P, et al. European consensus table on the use of botulinum toxin type A in adult spasticity. J Rehab Med 2009; 41: 13-25.
18. Ashworth B. Preliminary trial of carisoprodol in multiple sclerosis. Practitioner 1964. 192: 540-542.
19. Brashear A, Zafonte R, Corcoran M, et al. Inter- and intrarater reliability of the Ashworth Scale and the disability assessment scale in patients with upper-limb poststroke spasticity. Arch Phys Med Rehabil 2002; 83: 1349-1354.
20. MacDougall J. Analysis of dose-response studies-Emax model. In: Ting N, editor. Dose Finding in Drug Development, New York, NY: Springer; 2006. p 127-145.
21. Charles D, Shah M, VanDenburgh AM, et al. Clinically meaningful differences in Ashworth scale scores in patients suffering from chronic post-stroke upper limb spasticity. Neurology 2008; 70(11Suppl1): A205[P04.144].
22. SAS Institute Inc., 2004, SAS/STAT® user's guide, Version 9.1, Cary, NC: SAS Institute Inc.
23. Lieber RL, Steinman S, Barash IA, et al. Structural and functional changes in spastic skeletal muscle. Muscle Nerve 2004; 29: 615-627.
24. Allergan Pharmaceuticals. BOTOX® (OnabotulinumtoxinA). Package insert. ©2009. Allergan Pharmaceuticals, Inc., Irvine, California.